{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T04:15:44Z","timestamp":1772165744863,"version":"3.50.1"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,11,6]],"date-time":"2020-11-06T00:00:00Z","timestamp":1604620800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2020,11,6]],"date-time":"2020-11-06T00:00:00Z","timestamp":1604620800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001700","name":"the Japanese Ministry of Education, Culture, Sports, Science and Technology","doi-asserted-by":"crossref","award":["17K10534"],"award-info":[{"award-number":["17K10534"]}],"id":[{"id":"10.13039\/501100001700","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>\n                      S-1 and cyclophosphamide (CPA) can be given orally, and their combination may have great potential for treating metastatic breast cancer (MBC). A phase I study of sequential S-1 and CPA therapy was conducted in patients with MBC; the recommended doses that were determined for this regimen were 80\u2009mg\/m\n                      <jats:sup>2<\/jats:sup>\n                      \/day for S-1 and 100\u2009mg\/m\n                      <jats:sup>2<\/jats:sup>\n                      \/day for CPA. We then conducted a phase II study of this oral S-1 and CPA regimen.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This was a single-arm, open-label, single-center prospective phase II study to evaluate the efficacy of a sequential S-1 and CPA regimen for MBC. S-1 was administered orally 2\u00d7\/day for 14 consecutive days, and then CPA was administered orally 2\u00d7\/day for 14 consecutive days in a repeating 4-week\u2009cycle (S-1 for 2\u2009weeks, CPA for 2\u2009weeks). The primary endpoint was the overall response rate (ORR). Secondary endpoints included the overall survival (OS), progression-free survival (PFS), clinical benefit rate (CBR) and safety.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Thirty-six patients were enrolled in this study. The overall response was complete response in 0 (0%), partial response in 12 (33.3%), stable disease in 12 (33.3%), and progressive disease in 11 (30.1%) patients. The ORR was 33.3% (12\/36). The CBR was 66.7% (24\/36). The median PFS was 9.5\u2009months (95%CI: 7.8\u201312.6\u2009months). The median OS was 20.2\u2009months (95%CI: 15.0\u201325.4\u2009months) Grade 3\/4 adverse events included leukopenia in seven patients (19.4%). Dose reductions because of adverse events occurred in 12 patients (33.3%). There was no treatment-related mortality.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>The combination of sequential therapy with S-1 and CPA was tolerable and had efficacy with good disease control. Sequential therapy with S-1 and CPA may be a feasible new treatment option for patients with MBC; however, further study is warranted to explore the efficacy of this therapy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration<\/jats:title>\n                    <jats:p>\n                      JRCT,\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/jrct.hiph.go.jp\/latest-detail.jrcts031180296\">JRCTs031180296<\/jats:ext-link>\n                      . Registered 2 December 2019 \u2013 Retrospectively registered.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12885-020-07550-5","type":"journal-article","created":{"date-parts":[[2020,11,6]],"date-time":"2020-11-06T12:02:57Z","timestamp":1604664177000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Phase II study of sequential S-1 and cyclophosphamide therapy in patients with metastatic breast cancer"],"prefix":"10.1186","volume":"20","author":[{"given":"Keiko","family":"Yanai","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8357-391X","authenticated-orcid":false,"given":"Takaaki","family":"Fujii","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jun","family":"Horiguchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuko","family":"Nakazawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sasagu","family":"Kurozumi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sayaka","family":"Obayashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Reina","family":"Yajima","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ken","family":"Shirabe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,11,6]]},"reference":[{"key":"7550_CR1","doi-asserted-by":"publisher","first-page":"974","DOI":"10.1056\/NEJM199810013391407","volume":"14","author":"GN Hortobagyi","year":"1998","unstructured":"Hortobagyi GN. Treatment of breast cancer. N Engl J Med. 1998;14:974\u201384.","journal-title":"N Engl J Med"},{"key":"7550_CR2","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1007\/s10147-013-0547-4","volume":"19","author":"Y Suzuki","year":"2014","unstructured":"Suzuki Y, Ogiya R, Oshitanai R, Terao M, Terada M, Morioka T, Tsuda B, Niikura N, Okamura T, Saito Y, Tokuda Y. Feasibility and pharmacokinetics of combined therapy with S-1 and trastuzumab in patients with human epidermal growth factor receptor 2-positive metastatic or recurrent breast cancer. Int J Clin Oncol. 2014;19:274\u20139.","journal-title":"Int J Clin Oncol"},{"key":"7550_CR3","first-page":"905","volume":"38","author":"T Fujii","year":"2018","unstructured":"Fujii T, Horiguchi J, Yanagita Y, Koibuchi Y, Ikeda F, Uchida N, Kimura M, GUNMA BREAST CLINICAL CONFERENCE STUDY GROUP (GBCCSG). Phase II study of S-1 plus trastuzumab for HER2-positive metastatic breast cancer (GBCCSG-01). Anticancer Res. 2018;38:905\u20139.","journal-title":"Anticancer Res"},{"key":"7550_CR4","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1016\/S1470-2045(15)00411-8","volume":"17","author":"T Takashima","year":"2016","unstructured":"Takashima T, Mukai H, Hara F, Matsubara N, Saito T, Takano T, Park Y, Toyama T, Hozumi Y, Tsurutani J, Imoto S, Watanabe T, Sagara Y, Nishimura R, Shimozuma K. Ohashi Y, for the SELECT BC study group: Taxanes versus S-1 as the first-line chemotherapy for metastatic breast cancer (SELECT BC): an open-label, non-inferiority, randomized phase 3 trial. Lancet Oncol. 2016;17:90\u20138.","journal-title":"Lancet Oncol"},{"key":"7550_CR5","doi-asserted-by":"publisher","first-page":"3355","DOI":"10.1007\/s00520-012-1492-x","volume":"20","author":"K Shimozuma","year":"2012","unstructured":"Shimozuma K, Ohashi Y, Aranishi T, Morita S, Kuroi K, Ohsumi S, Makino H, Katsumata N, Kuranami M, Suemasu K, Watanabe T, Hausheer FH. Taxane-induced peripheral neuropathy and health-related quality of life in postoperative breast cancer patients undergoing adjuvant chemotherapy: N-SAS BC 02, a randomized clinical trial. Support Care Cancer. 2012;20:3355\u201364.","journal-title":"Support Care Cancer"},{"key":"7550_CR6","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/S0959-8049(01)00322-7","volume":"38","author":"A Sparreboom","year":"2002","unstructured":"Sparreboom A, de Jonge MJ, Verweij J. The use of oral cytotoxic and cytostatic drugs in cancer treatment. Eur J Cancer. 2002;38:18\u201322.","journal-title":"Eur J Cancer"},{"key":"7550_CR7","doi-asserted-by":"publisher","first-page":"2909","DOI":"10.1002\/cam4.1258","volume":"6","author":"H Ishiguro","year":"2017","unstructured":"Ishiguro H, Saji S, Nomura S, Tanaka S, Ueno T, Onoue M, Iwata H, Yamanaka T, Sasaki Y, Toi M. A phase I\/II pharmacokinetics\/pharmacodynamics study of irinotecan combined with S-1 for recurrent\/metastatic breast cancer in patients with selected UGT1A1 genotypes (the JBCRG-M01 study). Cancer Med. 2017;6:2909\u201317.","journal-title":"Cancer Med"},{"key":"7550_CR8","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1007\/BF02968301","volume":"11","author":"T Saek","year":"2004","unstructured":"Saek T, Takashima S, Sano M, Horikoshi N, Miura S, Shimizu S, Morimoto K, Kimura M, Aoyama H, Ota J, Noguchi S, Taguchi T. A phase II study of S-1 in patients with metastatic breast cancer\u2014a Japanese trial by the S-1 cooperative study group, Breast Cancer Working Group. Breast Cancer. 2004;11:194\u2013202.","journal-title":"Breast Cancer"},{"key":"7550_CR9","first-page":"3583","volume":"34","author":"T Takashima","year":"2014","unstructured":"Takashima T, Nakayama T, Yoshidome K, Kawajiri H, Kamigaki S, Tsurutani J, Arai T, Ito T, Komoike Y, Doi T, Masuda N, Miyauchi K, Miyoshi Y, Aakamoto J, Morita S, Taguchi T. Phase II study of S-1 in combination with trastuzumab for HER2-positive metastatic breast cancer. Anticancer Res. 2014;34:3583\u20138.","journal-title":"Anticancer Res"},{"key":"7550_CR10","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1186\/s12885-015-1289-7","volume":"15","author":"T Shigekawa","year":"2015","unstructured":"Shigekawa T, Osaki A, Sekine H, Sato N, Kanbayashi C, Sano H, Takeuchi H, Udea S, Nakamiya N, Sugitani I, Sugiyama M, Shimada H, Hirokawa E, Takahashi T, Saeki T. Safety and feasibility of adjuvant chemotherapy with S-1 in Japanese breast cancer patients after primary systemic chemotherapy: a feasibility study. BMC Cancer. 2015;15:253.","journal-title":"BMC Cancer"},{"key":"7550_CR11","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1023\/A:1008384820279","volume":"11","author":"JE Kurtz","year":"2000","unstructured":"Kurtz JE, Deplanque G, Borel G, Mathelin C, Pr\u00e9vost G, Poulin G, Barats JC, Bergerat JP, Chapelle-Marcillac I, Bardonnet M, Dufour P. Dose-finding study of oral idarubicin and cyclophosphamide in first-line treatment of elderly patients with metastatic breast cancer. Ann Oncol. 2000;11:229\u201330.","journal-title":"Ann Oncol"},{"key":"7550_CR12","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1093\/annonc\/mdf013","volume":"13","author":"M Colleoni","year":"2002","unstructured":"Colleoni M, Rocca A, Sandri TM, Zorzino L, Masci G, Nol\u00e9 F, Peruzzotti G, Robertson C, Orlando L, Cinieri S, de Braud F, Viale G, Goldhirsch A. Low-dose oral methotrexate and cyclophosphamide in metastatic breast cancer: antitumor activity and correlation with vascular endothelial growth factor levels. Ann Oncol. 2002;13:73\u201380.","journal-title":"Ann Oncol"},{"key":"7550_CR13","first-page":"529","volume":"32","author":"V Gebbia","year":"2012","unstructured":"Gebbia V, Boussen H, Valerio MR. Oral metronomic cyclophosphamide with and without methotrexate as palliative treatment for patients with metastatic breast carcinoma. Anticancer Res. 2012;32:529\u201336.","journal-title":"Anticancer Res"},{"key":"7550_CR14","first-page":"1009","volume":"27","author":"S Ohno","year":"2007","unstructured":"Ohno S, Mitsuyama S, Tamura K, Nishimura R, Tanaka M, Hamada Y, Kuroki S, The KYUSHU BREAST CANCER STUDY GROUP. Dosage of capecitabine and cyclophosphamide combination therapy in patients with metastatic breast cancer. Anticancer Res. 2007;27:1009\u201314.","journal-title":"Anticancer Res"},{"key":"7550_CR15","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1097\/CAD.0b013e328336acb1","volume":"21","author":"M Tanaka","year":"2010","unstructured":"Tanaka M, Takamatsu Y, Anan K, Ohno S, Nishimura R, Yamamoto Y, Masuda N, Mitsuyama S, Tamura K, KYUSHU BREAST CANCER STUDY GROUP. Oral combination chemotherapy with capecitabine and cyclophosphamide in patients with metastatic breast cancer: a phase II study. Anti-Cancer Drugs. 2010;21:453\u20138.","journal-title":"Anti-Cancer Drugs"},{"key":"7550_CR16","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1007\/s00280-011-1728-3","volume":"69","author":"Z Wang","year":"2012","unstructured":"Wang Z, Lu J, Leaw S, Hong X, Wang J, Shao Z, Hu X. An all-oral combination of metronomic cyclophosphamide plus capecitabine in patients with anthracycline- and taxane-pretreated metastatic breast cancer: a phase II study. Cancer Chemother Pharmacol. 2012;69:515\u201322.","journal-title":"Cancer Chemother Pharmacol"},{"key":"7550_CR17","first-page":"3453","volume":"23","author":"Y Ogawa","year":"2003","unstructured":"Ogawa Y, Ishikawa T, Chung SH, Ikeda K, Takashima T, Onoda N, Nakata B, Nishiguchi Y, Hirakawa K. Oral UFT and cyclophosphamide combination chemotherapy for metastatic breast cancer. Anticancer Res. 2003;23:3453\u20137.","journal-title":"Anticancer Res"},{"key":"7550_CR18","first-page":"1175","volume":"40","author":"J Horiguchi","year":"2013","unstructured":"Horiguchi J, Takata D, Rokutanda N, Nagaoka R, Tokiniwa H, Odawara H, Kikuchi M, Sato A, Takeyoshi I. Phase I study of sequential S-1 and cyclophosphamide therapy in patients with metastatic breast cancer. Gan To Kagaku Ryoho. 2013;40:1175\u201380.","journal-title":"Gan To Kagaku Ryoho"},{"key":"7550_CR19","doi-asserted-by":"publisher","first-page":"3386","DOI":"10.1158\/0008-5472.CAN-05-4411","volume":"66","author":"R Munoz","year":"2006","unstructured":"Munoz R, Man S, Shaked Y, Lee CR, Wong J, Francia G, Kerbel RS. Highly efficacious nontoxic preclinical treatment for advanced metastatic breast cancer using combination oral UFT-cyclphosphamide metronomic chemotherapy. Cancer Res. 2006;66:3386\u201391.","journal-title":"Cancer Res"},{"key":"7550_CR20","first-page":"2185","volume":"5","author":"Y Yonekura","year":"1999","unstructured":"Yonekura Y, Basaki Y, Chikahisa L, Okabe S, Hashimoto A, Miyadera K, Wierzba K, Yamada Y. UFT and its metabolites inhibit the angiogenesis induced by murine renal cell carcinoma, as determined by a dorsal air sac assay in mice. Clin Cancer Res. 1999;5:2185\u201391.","journal-title":"Clin Cancer Res"},{"key":"7550_CR21","doi-asserted-by":"publisher","first-page":"1627","DOI":"10.1038\/sj.bjc.6601350","volume":"89","author":"M Yoshimoto","year":"2003","unstructured":"Yoshimoto M, Tada K, Tokudome N. Kutomi Gm Tanabe M, Goto T, Nishimura S, Makita M, Kasumi F: the potential for oral combination chemotherapy of 5\u2032-deozy-5-fluorouridine, a 5-FU prodrug, and cyclophosphamide for metastatic breast cancer. Br J Cancer. 2003;89:1627\u201332.","journal-title":"Br J Cancer"},{"key":"7550_CR22","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1200\/JCO.2003.06.014","volume":"21","author":"T Tominaga","year":"2003","unstructured":"Tominaga T, Koyama H, Toge T, Miura S, Sucimachi K, Yamaguchi S, Hirata K, Monden Y, Nomura Y, Toi M, Kimijima I, Noguchi S, Sonoo H, Asaishi K, Ikeda T, Morimoto T, Ota J, Ohashi Y, Abe O. Randomized controlled trial comparing oral doxifluridine plus oral cyclophosphamide with doxifluridine alone in women with node-positive breast cancer after primary surgery. J Clin Oncol. 2003;21:991\u20138.","journal-title":"J Clin Oncol"},{"key":"7550_CR23","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1038\/sj.bjc.6602680","volume":"93","author":"D Ghersi","year":"2005","unstructured":"Ghersi D, Wilcken N, Simes RJ. A systematic review of taxane-containing regimens for metastatic breast cancer. Br J Cancer. 2005;93:293\u2013301.","journal-title":"Br J Cancer"},{"key":"7550_CR24","doi-asserted-by":"publisher","first-page":"2140","DOI":"10.1002\/pon.3268","volume":"22","author":"K Nozawa","year":"2013","unstructured":"Nozawa K, Shimizu C, Kakimoto M, Mizota Y, Yamamoto S, Takahashi Y, Ito A, Izumi H, Fujiwara Y. Quantitative assessment of appearance changes and related distress in cancer patients. Psychooncology. 2013;22:2140\u20137.","journal-title":"Psychooncology"},{"key":"7550_CR25","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1007\/s10384-012-0127-6","volume":"56","author":"T Sasaki","year":"2012","unstructured":"Sasaki T, Miyashita H, Miyanaga T, Yamamoto K, Sugiyama K. Dacryoendoscopic observation and incidence of canalicular obstruction\/stenosis associated with S-1, an oral anticancer drug. Jpn J Ophthalmol. 2012;56:214\u20138.","journal-title":"Jpn J Ophthalmol"},{"key":"7550_CR26","doi-asserted-by":"publisher","first-page":"2065","DOI":"10.1093\/annonc\/mds106","volume":"23","author":"N Kim","year":"2012","unstructured":"Kim N, Park C, Park DJ, Kim HH, Kim S, Kim YJ, Lee JS, Bang YJ, Khwarg SI, Choung H, Lee MJ, Lee KW. Lacrimal drainage obstruction in gastric cancer patients receiving S-1 chemotherapy. Ann Oncol. 2012;23:2065\u201371.","journal-title":"Ann Oncol"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-020-07550-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12885-020-07550-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-020-07550-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,11,9]],"date-time":"2020-11-09T16:06:18Z","timestamp":1604937978000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/s12885-020-07550-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11,6]]},"references-count":26,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["7550"],"URL":"https:\/\/doi.org\/10.1186\/s12885-020-07550-5","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-22934\/v3","asserted-by":"object"},{"id-type":"doi","id":"10.21203\/rs.3.rs-22934\/v1","asserted-by":"object"},{"id-type":"doi","id":"10.21203\/rs.3.rs-22934\/v2","asserted-by":"object"}]},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,11,6]]},"assertion":[{"value":"15 April 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 October 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 November 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This study was conducted in accordance with the Declaration of Helsinki, and the protocol was approved by the Clinical Ethics Committee of Gunma University. Written consent was obtained from all patients for the use of their records and imaging in future studies.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1068"}}